Anika Therapeutics (STU:AKP) Margin of Safety % (DCF Earnings Based): N/A (As of Jun. 28, 2026)


STU:AKP Anika Therapeutics Inc STU:AKP
63 GF Score
Price €13.10
GF Value €17.79
Valuation Modestly Undervalued
! 4 Warning Signs
View Full Analysis

What is Anika Therapeutics Margin of Safety % (DCF Earnings Based)?

Margin of Safety % (DCF Earnings Based) = (Intrinsic Value: DCF (Earnings Based) - Current Price) / Intrinsic Value: DCF (Earnings Based).

Note: Discounted Earnings model is only suitable for predictable companies (Business Predictability Rank higher than 1-Star). If the company's Predictability Rank is 1-Star or Not Rated, result may not be accurate due to the low predictability of business and the data will not be stored into our database.

Anika Therapeutics's Predictability Rank is 1-Star. Thus, the DCF related results in the screener and portfolio will appear as zero and Margin of Safety % (DCF Earnings Based) is not calculated.

STU:AKP vs LFCR, NIKA, DERM: Margin of Safety % (DCF Earnings Based) Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Anika Therapeutics's Margin of Safety % (DCF Earnings Based), along with its competitors' market caps and Margin of Safety % (DCF Earnings Based) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Anika Therapeutics Margin of Safety % (DCF Earnings Based) vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Anika Therapeutics's Margin of Safety % (DCF Earnings Based) distribution charts can be found below:

* The bar in red indicates where Anika Therapeutics's Margin of Safety % (DCF Earnings Based) falls into.


STU:AKP
63GF Score
Anika Therapeutics Inc STU:AKP
Margin of Safety % (DCF Earnings Based) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Anika Therapeutics (STU:AKP) Overvalued in 2026?

Based on GuruFocus' analysis, Anika Therapeutics stock appears to be undervalued. The current stock price of €13.10 is trading 26.4% below its estimated GF Value™ of €17.79. GuruFocus considers Anika Therapeutics to be Modestly Undervalued.

Key valuation signals for STU:AKP:

  • Margin of Safety % (DCF Earnings Based): N/A
  • GF Value™: €17.79 vs. price of €13.10 (26.4% below fair value)
  • GF Score™: 63/100 with 4 warning signs

No single metric tells the full story. See the STU:AKP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Anika Therapeutics Business Description

Other Exchanges ANIK:USA
Address 32 Wiggins Avenue, Bedford, MA, USA, 01730
Anika Therapeutics Inc operates in the OA Pain Management and regenerative solutions space, focusing on early intervention orthopedics. The company leverages proprietary hyaluronic acid (HA) technology to develop differentiated products and provides products and services. Its OA Pain Management products include Orthovisc, Monovisc, and Cingal. Monovisc and Orthovisc are single- and multi-injection HA viscosupplement products indicated for pain relief from OA conditions and are generally administered to patients in an office setting. In the United States, Monovisc and Orthovisc are marketed exclusively by Johnson & Johnson MedTech. It generates maximum revenue from the OEM Channel and derives the majority of its revenue from the United States, with a presence in Europe and other countries.
63GF Score

Get the complete analysis for STU:AKP

Margin of Safety % (DCF Earnings Based) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€13.10
Price
€17.79
GF Value